Annexon, a Phase 1 biotech developing therapies for rare autoimmune diseases, raised $251 million by offering 14.8 million shares at $17, above the narrowed range of $15 to $16. The company offered 2.3 million more shares than anticipated. It originally planned to offer 10 million shares at a range of $14 to $16, before increasing its proposed deal size on Thursday morning. At pricing, the company commands a fully diluted market value of $640 million.
Annexon plans to list on the Nasdaq under the symbol ANNX. J.P. Morgan, BofA Securities, and Cowen acted as lead managers on the deal.
Degenerative disease biotech Annexon prices further upsized IPO at $17, above the range
July 24, 2020

